How to buy Magenta Therapeutics stock (MGTA)

Magenta Therapeutics is a biotechnology business based in the US. Magenta Therapeutics shares (MGTA) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.22 – the same closing value as a week prior. Magenta Therapeutics employs 67 staff and has a market cap (total outstanding shares value) of 0.00.

Our top picks for where to buy Magenta Therapeutics stock

Buy Magenta Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Magenta Therapeutics stock price (NASDAQ: MGTA)

Use our graph to track the performance of MGTA stocks over time.

Magenta Therapeutics shares at a glance

• Key figures

Information last updated 2024-06-30.

Latest market close	$13.22
52-week range	$0.00 - $0.00
50-day moving average more info button	$0.78
200-day moving average more info button	$0.77
Wall St. target price	$1.00
PE ratio more info button	N/A
Dividend yield more info button	$0 (0%)
Earnings per share (TTM) more info button	$-1.11

Is it a good time to buy Magenta Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Magenta Therapeutics price performance over time

Historical closes compared with the close of $13.22 from 2023-09-20

1 week (2024-10-19)	N/A
1 month (2024-09-26)	N/A
3 months (2024-07-26)	N/A
6 months (2024-04-26)	N/A

1 year (2023-10-26)	N/A
2 years (2022-10-28)	957.60%
3 years (2021-10-29)	106.56%
5 years (2019-10-30)	25.43%

Magenta Therapeutics financials

Gross profit TTM	$0
Return on assets TTM	-28.85%
Return on equity TTM	-65.34%
Profit margin	0%
Book value	$1.24
Market Capitalization more info button	$45.1 million

TTM: trailing 12 months

Magenta Therapeutics share dividends

We're not expecting Magenta Therapeutics to pay a dividend over the next 12 months.

Magenta Therapeutics share price volatility

Over the last 12 months, Magenta Therapeutics's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Magenta Therapeutics's is 2.1195. This would suggest that Magenta Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Magenta Therapeutics overview

Magenta Therapeutics, Inc. , a biotechnology company focus on improving stem cell transplantation. Its product candidates are designed to bring the curative power of stem cell transplant to patients with blood cancers, genetic diseases, and autoimmune diseases. The company's product portfolio includes MGTA-117, an anti-CD117 antibody conjugated to an amanitin payload that targets hematopoietic stem cells (HSCs) and leukemia cells; and MGTA-45, an anti-human CD45 antibody conjugated to a DNA-interacting payload for HSCs, leukemia cells, and immune cells. In addition, it focus on development of ADC-based conditioning program that targets a receptor of T cells; and novel conditioning and translation stem cell sciences, as well as develops cell therapy program, E478, which is a small molecule aryl hydrocarbon receptor antagonist for stem cell-based gene therapy and genome editing. In addition, the company has a research and clinical collaboration agreement with AVROBIO, Inc. for the treatment of lysosomal storage disorders; and Beam Therapeutics, Inc.

Frequently asked questions

What percentage of Magenta Therapeutics is owned by insiders or institutions?
Currently 2.227% of Magenta Therapeutics shares are held by insiders and 62.639% by institutions. How many people work for Magenta Therapeutics?
Latest data suggests 67 work at Magenta Therapeutics. When does the fiscal year end for Magenta Therapeutics?
Magenta Therapeutics's fiscal year ends in December. Where is Magenta Therapeutics based?
Magenta Therapeutics's address is: 100 Technology Square, Cambridge, MA, United States, 02139 What is Magenta Therapeutics's ISIN number?
Magenta Therapeutics's international securities identification number is: US55910K1088 What is Magenta Therapeutics's CUSIP number?
Magenta Therapeutics's Committee on Uniform Securities Identification Procedures number is: 55910K108